AKEBIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 134.55K shares, a 16.00% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 28.42K shares, a 95.30% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 67.23K shares, a 51.20% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 418.30K shares, a 17992.56% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.21M shares, a 171.44% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 444.24K shares, a 19643.96% increase from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 2.25K shares.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 134.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 648.51K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 28.42K shares 10-Q · filed 2026-05-07 | 629.95K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 67.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 1.21M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 418.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 1.28M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 116.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 860.41K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 604.33K shares 10-Q · filed 2025-05-08 | 768.30K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 137.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 444.24K shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 2.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2024-06-30 | 23.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | |
| 2024-03-31 | 280.26K shares 10-Q · filed 2024-05-09 | |
| 2023-12-31 | 2.25K shares 10-K · filed 2024-03-14 | |
| 2022-06-30 | 142.44K shares 10-Q · filed 2023-08-28 | |
| 2021-12-31 | 0.00 shares 10-K/A · filed 2023-08-28 | |
| 2017-12-31 | 291.44K shares 10-K · filed 2018-03-12 | |
| 2016-12-31 | 86.63K shares 10-K · filed 2017-03-06 | |
| 2015-12-31 | 218.67K shares 10-K · filed 2016-03-14 | |
| 2014-12-31 | 116.39K shares 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |